RayKnowChina Research Map
Shortlist0

Not yet recruitingHepatocellular carcinomaPhase not stated

Registered title, quoted from ClinicalTrials.gov

TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Zhongda Hospital, Southeast University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorZhongda Hospital, Southeast University东南大学附属中大医院NanjingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07836309, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 16 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed hepatocellular carcinoma (HCC), or patients who meet the clinical diagnostic criteria for primary liver cancer;

    Inclusion criterion 1

  3. Child-Pugh class A5 to B7;

    Inclusion criterion 8

  4. Received treatment with tislelizumab and lenvatinib, with the interval between the first administration of the two drugs ≤1 week;

    Inclusion criterion 5

    In the experimental group, TACE was performed within 3 months before or after treatment with tislelizumab and lenvatinib;

    Inclusion criterion 6

  5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1;

    Inclusion criterion 9

  6. At least one measurable intrahepatic lesion according to RECIST 1.1 criteria.

    Inclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07836309, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Histologically or cytologically confirmed hepatocellular carcinoma (HCC), or patients who meet the clinical diagnostic criteria for primary liver cancer;
  • Age ≥18 years at the time of HCC diagnosis;
  • Barcelona Clinic Liver Cancer (BCLC) stage C;
  • No prior systemic therapy for HCC (including chemotherapy, molecular targeted therapy, or immunotherapy);
  • Received treatment with tislelizumab and lenvatinib, with the interval between the first administration of the two drugs ≤1 week;
  • In the experimental group, TACE was performed within 3 months before or after treatment with tislelizumab and lenvatinib;
  • After TACE, patients received at least one cycle of combination therapy with tislelizumab and lenvatinib, including cTACE and DEB-TACE;
  • Child-Pugh class A5 to B7;
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1;
  • At least one measurable intrahepatic lesion according to RECIST 1.1 criteria.

Exclusion Criteria:

  • Known fibrolamellar HCC, sarcomatoid HCC, or combined hepatocellular-cholangiocarcinoma histological types;
  • Complete obstruction of the main portal vein with insufficient collateral compensation;
  • Uncontrollable ascites or hepatic encephalopathy;
  • Incomplete clinical data or missing essential information;
  • Presence of other primary malignant tumors in addition to the diagnosis of liver cancer;
  • Participation in other interventional studies prior to treatment;
  • Other conditions deemed unsuitable for inclusion by the investigators.

Quoted from ClinicalTrials.gov, NCT07836309, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07836309, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07836309